ADMS News and Press, Adamas Pharmaceuticals Inc. From 08/28/19

Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...

More than a year ago, we wrote a series of articles on Adamas Pharmaceuticals ( ADMS ); in one of these, we said that ADMS is not a one-trick pony and that Gocovri's eventual label expansion in walking impairment in MS patients will be a far bigger revenue-generator than its existing approva...

Adamas Pharmaceuticals ( ADMS ) recently announced their Q2 earnings report that disclosed that the company beat on GAAP EPS by $0.12, but missed by $0.11M on revenue. During the earnings call, the company publicized their two priorities for the remainder of 2019. One, driving towards th...

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Peter Vozzo - Westwicke Partners Gregory Went - Founder, Chairman and Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Alfred Merriweat...

Adamas Pharma (NASDAQ: ADMS ): Q2 GAAP EPS of -$0.90 beats by $0.12 . Revenue of $12.69M (+67.6% Y/Y) misses by $0.11M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

- Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment completed, with topline results expected late Q4 2019...

EMERYVILLE, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday, August 8, 2019, after market close. Subsequently, Adamas’ management team will host a conf...

EMERYVILLE, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced a retrospective data analysis from pooled Phase 3 tria...

EMERYVILLE, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, C...

EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as it...